RSV (Nirsevimab/Pediatric)
RSV Prophylaxis — Pediatric (Nirsevimab / mRNA-1345)
Platform: Monoclonal antibody / mRNA (trial)
Monoclonal antibody and vaccine candidates that protect infants against respiratory syncytial virus (RSV), the most common cause of infant hospitalization.
Immunology Sections
Curated section analysis in progress
Structured immunology sections — mechanism, immune response, molecular signatures, correlates of protection, and more — are being prepared by the Precision Vaccines Program team. In the meantime, verified references and live literature from PubMed, Semantic Scholar, and Wikipedia are available below.
Wikipedia Overview
Full article ↗Nirsevimab, sold under the brand name Beyfortus, is a human recombinant monoclonal antibody with activity against respiratory syncytial virus (RSV). It is a respiratory syncytial virus (RSV) F protein‑directed fusion inhibitor that is designed to bind to the fusion protein on the surface of the RSV virus.
PubMed Literature
Search PubMed ↗No PubMed results retrieved.
Semantic Scholar
Search S2 ↗No Semantic Scholar results retrieved.